FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Disclosed is a molecule specifically binding ligand-1 protein programmable death (PDL1) and use thereof, for example, as part of a pharmaceutical composition for treating or preventing cancer. Invention also discloses a nucleic acid molecule encoding said PDL1-binding molecule, an expression vector and a host cell for producing a PDL1-binding molecule.
EFFECT: invention provides binding with PDL1 with high affinity and specificity, which leads to blocking PDL1 binding to PD-1.
20 cl, 24 dwg, 7 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME | 2014 |
|
RU2662991C2 |
| FUSED IMMUNOMODULATORY PROTEINS AND METHODS FOR PRODUCTION THEREOF | 2014 |
|
RU2698975C2 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2840536C1 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2841589C1 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
| NOVEL ANTI-FGFR2B ANTIBODIES | 2020 |
|
RU2840537C1 |
| NANOANTIBODY SPECIFICALLY BINDING MUC1 PROTEIN, METHOD OF MUC1 PROTEIN DETECTION BY NANOANTIBODIES | 2012 |
|
RU2493165C1 |
| CD8 BINDING AGENTS AND USE THEREOF | 2020 |
|
RU2830301C1 |
| NEW MONOCLONAL ANTIBODIES TO PROGRAMMED CELL DEATH 1 (PD-1) PROTEIN | 2016 |
|
RU2757316C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2013 |
|
RU2599417C2 |
